Regular health assessments will help you stay on track

Managing Morquio A is a team effort

In partnership with your geneticist and healthcare team, you can take charge of your Morquio A. Your healthcare team can help you determine which assessments are most important for you and how often you should have them done.

Your geneticist may take the lead in coordinating many aspects of your treatment plan, such as tests and visits, as well as arranging for VIMIZIM® (elosulfase alfa) treatment.

Image

Managing Morquio A is a team effort

In partnership with your geneticist and healthcare team, you can take charge of your Morquio A. Your healthcare team can help you determine which assessments are most important for you and how often you should have them done.

Your geneticist may take the lead in coordinating many aspects of your treatment plan, such as tests and visits, as well as arranging for VIMIZIM® (elosulfase alfa) treatment.

 

Overview of assessments

Because Morquio A is progressive, it is important to keep track of your symptoms. There are a number of assessments that will help you and your healthcare team track your symptoms and progress. The Assessments Overview Chart provides a convenient summary of the various types of assessments and when they are recommended. You can use this with your doctor to help manage your Morquio A.

    Assessment chart for regular check-ups on VIMIZIM

    CT, computed tomography; ECG, electrocardiogram; MRI, magnetic resource imaging; QoL, quality of life; 6MWT, 6-minute walk test.

    This chart has been adapted from the “International Guidelines for the Management and Treatment of Morquio A Syndrome.”

    Overview of assessments

    Because Morquio A is progressive, it is important to keep track of your symptoms. There are a number of assessments that will help you and your healthcare team track your symptoms and progress. The Assessments Overview Chart provides a convenient summary of the various types of assessments and when they are recommended. You can use this with your doctor to help manage your Morquio A.

    Image

    CT, computed tomography; ECG, electrocardiogram; MRI, magnetic resource imaging; QoL, quality of life; 6MWT, 6-minute walk test.

    This chart has been adapted from the “International Guidelines for the Management and Treatment of Morquio A Syndrome.”

      INDICATION
      VIMIZIM® (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

      IMPORTANT SAFETY INFORMATION

      Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM® (elosulfase alfa) infusions. Typical signs of anaphylaxis include cough, rash, throat tightness, hives, flushing, changes in skin color, low blood pressure, shortness of breath, chest pain, and gastrointestinal symptoms such as nausea, abdominal pain, retching, and vomiting. Contact your doctor or get medical help right away if these symptoms occur during or after VIMIZIM infusions. If you have a respiratory illness, you may be at risk for a sudden worsening of your condition, and you may require additional monitoring.

      VIMIZIM is a prescription medicine. Before treatment with VIMIZIM, it is important to discuss your medical history with your doctor. Tell your doctor if you are sick or taking any medication and if you are allergic to any medicines. Also tell your doctor if you are pregnant, planning to become pregnant, or are a nursing mother. Your doctor will decide if VIMIZIM is right for you. If you have questions or would like more information about VIMIZIM, contact your doctor.

      Anaphylaxis can occur during any VIMIZIM infusion and up to three hours after any infusion, and hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion.

      Serious and severe reactions can happen with VIMIZIM treatment, including life-threatening allergic reactions (anaphylaxis), hives, swelling, cough, shortness of breath, and flushing. You should receive medication such as antihistamines before VIMIZIM infusions to reduce the risk of reactions. If a reaction occurs, the infusion should be slowed or stopped and you may be given additional medication. If a severe reaction occurs, the infusion should be stopped immediately and you will receive appropriate medical treatment.

      If you have acute febrile or respiratory illness at the time of VIMIZIM infusion you may be at higher risk of life-threatening complications from hypersensitivity reactions. If you use supplemental oxygen or continuous positive airway pressure (CPAP) you should have it available during your infusion in the event of a sudden reaction, or extreme drowsiness/sleep from antihistamines.

      Spinal cord damage may occur due to the natural MPS IVA disease process. Signs of spinal cord injury include back pain, numbness and paralysis, and loss of bladder and bowel control. Contact your doctor immediately if you develop any of these symptoms.

      The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all of the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.

      Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

      For more information, call BioMarin RareConnections at 1-866-906-6100.

      Please see full Prescribing Information, including important warning.